Jeffrey Eisele
CIK 1827326 · Chief Development Officer · last filed 2025-01-30
Jeffrey Eisele is a Chief Development Officer who has filed 24 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing shows the insider sold $8.2K of APLS on Jan 30, 2025. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
24
-$1.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Development Officer | 55,312 | $41.03 | $2.27M | -$1.49M | 24 | 2025-01-30 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −278 | -$8.2K | EDGAR |
| 2025-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,291 | -$39.3K | EDGAR |
| 2025-01-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −264 | -$7.6K | EDGAR |
| 2024-12-27 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −63 | -$2.1K | EDGAR |
| 2024-01-31 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,250 | -$81.5K | EDGAR |
| 2024-01-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −7,378 | -$469.9K | EDGAR |
| 2024-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,607 | -$104.4K | EDGAR |
| 2024-01-18 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −5,207 | -$341.5K | EDGAR |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +19,070 | -$29.3K | EDGAR |
| 2023-12-28 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −303 | -$18.1K | EDGAR |